Eli Lilly to Focus on Cancer, Diabetes in China, CEO Says

Eli Lilly & Co. will introduce more than a dozen products in China, including drugs for diabetes and cancer, in the next five years to help maintain sales growth, Chief Executive Officer John Lechleiter said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.